Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fucose - AUG Therapeutics

Next Previous
Drug Profile

Fucose - AUG Therapeutics

Alternative Names: 6-deoxy-L-galactose - AUG Therapeutics; AVTX 803; CERC 803; Deoxygalactose - AUG Therapeutics; L-Fucose - AUG Therapeutics; L-Fucose crystalline powder - AUG Therapeutics

Latest Information Update: 02 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cerecor
  • Developer AUG Therapeutics
  • Class Deoxy sugars; Hexoses; Small molecules
  • Mechanism of Action Fucose replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn error metabolic disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase III Leukocyte-Adhesion Deficiency Syndrome

Most Recent Events

  • 31 Oct 2023 AUG Therapeutics acquires Fucose from Avalo Therapeutics
  • 10 Apr 2023 Avalo Therapeutics initiates a phase III trial Leukocyte adhesion deficiency syndrome (In infants, In children, In adolescents, In adults, In the elderly) in USA (PO) (NCT05754450)
  • 02 Aug 2022 Phase-III clinical trials in Leukocyte adhesion deficiency syndrome in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top